(PharmaNewsWire.Com, January 03, 2017 ) Allergy Immunotherapies Market, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years and discussion of the key vendors effective in this market. To calculate the market size, the report considers the revenue generated from the sales of Allergy Immunotherapies globally.
The Allergy Immunotherapies Market report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.
Following Companies Are Key Players of the Allergy Immunotherapies Market:
ALK-Abello Stallergenes Merck Group Allergy Therapeutics
Other Prominent Vendors of Allergy Immunotherapies Market Are:
Adamis Pharmaceuticals Aimmune Therapeutics Anergis ASIT biotech Biomay Circassia
“A trend propelling market growth is the advent of SPIRE. The SPIRE allergy immunotherapy is a novel method to treat allergies. This therapy uses the proprietary MicronJet system to maximize the immune response. MicronJet, a novel device approved in the US and the EU, provides patient friendly, consistent, and intradermal administration of drugs. Vendors are showing an interest in this patented novel synthetic pharmaceutical technology due to its ease of use and compatibility compared to the complex techniques of existing immunotherapies.”
According to the Allergy Immunotherapies Market report, a key growth driver is the presence of high unmet medical needs. Though existing therapies are highly effective in relieving and controlling symptoms, the market still requires drugs that reduce inflammation and irreversible airway remodeling. In Europe, the US, and Japan, an estimated 39 million individuals are not in control of their respiratory-related allergies, as only a few drugs provide appropriate treatment; only about 4.5 million receive AIT. Globally, only 55% of all the allergic rhinitis cases have been diagnosed. In addition, allergic rhinitis and allergic asthma are chronic diseases that cannot be cured, and most patients needed lifelong treatment and lifestyle adjustments. Thus, an unmet medical need exists for novel targeted drugs that treat the underlying cause of these conditions.
Report also presents Geographical Segmentation analysis of Allergy Immunotherapies Market of Americas, APAC, EMEA region.
Further, the Allergy Immunotherapies Market report states that one challenge that could hamper market growth is poor patient adherence and high dropout rates from treatment programs.
Key questions answered in Allergy Immunotherapies market report:
What will the Allergy Immunotherapies market size be in 2020 and what will the growth rate be? What are the key market trends? What is driving Allergy Immunotherapies market? What are the challenges to Allergy Immunotherapies market growth? Who are the key vendors in Allergy Immunotherapies market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors?
Market Reports World is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: